Brief: Theranexus Announces Updates On Batten-1 Program With BBDF

Thx Pharma SA

05/01/2023 17:09

Jan 5 (Reuters) - Theranexus SA  ALTHX.PA :
    * NEW ADVANCE TO THE THERANEXUS AND BBDF BATTEN-1 PROGRAM
FOR
JUVENILE BATTEN DISEASE (CLN3)
    * INITIAL RESULTS OF THEIR PHASE I/II CLINICAL TRIAL FOR
JUVENILE
BATTEN DISEASE (CLN3)
    * PROTOCOL OF PHASE III TRIAL TO LAUNCH PIVOTAL CLINICAL
TRIAL
INVOLVING PEDIATRIC COHORT DURING 2023

Source text for Eikon:  ID:nACT77910 
Further company coverage:  ALTHX.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))